WO1993022029A1 - Procede et dispositif pour traiter des fluides de medicaments a administration parenterale contenant une emulsion - Google Patents

Procede et dispositif pour traiter des fluides de medicaments a administration parenterale contenant une emulsion Download PDF

Info

Publication number
WO1993022029A1
WO1993022029A1 PCT/US1993/004021 US9304021W WO9322029A1 WO 1993022029 A1 WO1993022029 A1 WO 1993022029A1 US 9304021 W US9304021 W US 9304021W WO 9322029 A1 WO9322029 A1 WO 9322029A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
parenteral
emulsion
containing medicament
filtration element
Prior art date
Application number
PCT/US1993/004021
Other languages
English (en)
Inventor
Thomas J. Bormann
Vlado I. Matkovich
Thomas C. Gsell
Gerard R. Delgiacco
Original Assignee
Pall Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pall Corporation filed Critical Pall Corporation
Priority to DE69326947T priority Critical patent/DE69326947T2/de
Priority to CA002132422A priority patent/CA2132422C/fr
Priority to EP93910894A priority patent/EP0637986B1/fr
Priority to JP51950693A priority patent/JP3169612B2/ja
Priority to GB9420642A priority patent/GB2280860B/en
Publication of WO1993022029A1 publication Critical patent/WO1993022029A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/147—Microfiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/165—Filtering accessories, e.g. blood filters, filters for infusion liquids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D19/00—Degasification of liquids
    • B01D19/0031—Degasification of liquids by filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D36/00—Filter circuits or combinations of filters with other separating devices
    • B01D36/001—Filters in combination with devices for the removal of gas, air purge systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
    • B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
    • B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/18—Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
    • B01D63/08—Flat membrane modules
    • B01D63/087—Single membrane modules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/12—Composite membranes; Ultra-thin membranes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/12—Composite membranes; Ultra-thin membranes
    • B01D69/1214—Chemically bonded layers, e.g. cross-linking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/12—Composite membranes; Ultra-thin membranes
    • B01D69/1216—Three or more layers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/12—Composite membranes; Ultra-thin membranes
    • B01D69/1218—Layers having the same chemical composition, but different properties, e.g. pore size, molecular weight or porosity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/165—Filtering accessories, e.g. blood filters, filters for infusion liquids
    • A61M2005/1657—Filter with membrane, e.g. membrane, flat sheet type infusion filter

Definitions

  • This invention relates to a method, system, and device for treating parenteral fluids.
  • parenteral fluids e.g., involving an administrative pathway other than one which involves the gastrointestinal tract
  • parenterally administered drugs is preferred.
  • Parenteral administration typically includes intravascular, intramuscular, or subcutaneous routes, but drugs may be applied to the skin, injected intradermally, inhaled or absorbed.
  • parenteral administration of fluids such as medicaments may be advantageous, it is not without drawbacks.
  • infection during the administration process is a potential complication, even though medicaments may be produced according to strict regulations, e.g., strict aseptic protocols, and the preparation may be highly uniform. Microbiologic contamination of parenterally administered substances may occur during their preparation, during administration, or via manipulation of a part of the administration set, thus leading to infection.
  • the threat of infection is of particular concern when administering parenteral fluids to debilitated patients with compromised immune systems, since their resistance to infection may be low.
  • parenterally administered medicaments particularly those containing lipids, may provide a medium for the rapid growth of potentially pathogenic microorganisms.
  • fungal organisms such as Candida albicans.
  • bacterial organisms such as Escherichia coli, Pseudomonas aeruqinosa. and Staphylococcus spp. may thrive in a variety of medicament administration systems, therefore posing a threat of infection. Additionally, pyrogenic substances, for example, endotoxins in the parenteral fluid, can induce fever. Moreover, failure to maintain aseptic protocols may lead to infection caused by pathogenic contaminants.
  • parenterally administered fluids particularly those medicaments including an oil-in-water emulsion wherein lipids are a primary component of the emulsion.
  • the lipid emulsion is typically stabilized by an emulsifying agent which gives the emulsion droplets a negative surface charge.
  • the negatively charged emulsion droplets repel each other, which helps maintain the homogenous dispersion of the lipid particles within the internal phase of the emulsion.
  • Xf homogenous dispersion is not maintained, the emulsion may destabilize, and the particles may aggregate in larger numbers, and coalesce to form larger particles. This may pose a great threat to the patient if this parenteral fluid is administered, since particles about 5 micrometers or greater in size may block small pulmonary vessels, causing a potentially dangerous fat embolus.
  • microbiological filters are specifically contra-indicated by some manufacturers of parenteral medicaments. It is believed that the filter may cause a breakdown of the emulsion, and the filter may exhibit limited flow capacity, may plug easily and/or may bind or restrict the flow of the medicament. Moreover, the pore rating of a microbiological filter may be expected to block desirable material, such as lipid particles in an emulsion, since those particles may have a diameter of about .5 micrometers or less.
  • the decrease in flow of parenterally administered medicaments which pass through a microbiological filter may pose an additional drawback—excessive pressure build up.
  • Excessive pressure build up may present a serious problem since the liquid medicament may be administered using a pump designed to operate at relatively low pressures, e.g., typically less than 15 psi. Because these pumps are not engineered to operate at higher pressures, the administration system typically includes an occlusion alarm which shuts down the pump at a relatively low pressure. This places an additional constraint on the use of anti-microbiological filters having a pore rating below about 1.2 micrometers, since these filters may exhibit pressure build up, flow restriction, and plugging that leads to pump shut down.
  • parenteral fluids typically reflects an unsatisfying compromise.
  • strict aseptic techniques and single use products may decrease contamination and growth without adversely affecting the emulsion or the flow rate, but these techniques still fail to provide for the administration of a bacteria-depleted infusate to the patient.
  • pore ratings sufficient to remove microorganisms are typically too small to be used effectively with parenteralizids and with some medicaments administered parenterally. This is an especially unsatisfying compromise since bacteria and/or fungi are likely to grow in media used for parenteral medicaments.
  • a filter device for a parenterally administered medicament having an enhanced capability for filtration of undesirable matter from a parenteral medicament fluid, especially to preclude microorganisms and fine. particles from entering the infusate while passing the larger, desirable, parenteral medicament fluid components therethrough.
  • a filter for processing a parenteral medicament fluid including a lipid emulsion and a medicament to remove bacteria from an infusate. Disclosure of Invention
  • the present invention relates to processes and systems for treating a parenteral medicament fluid to separate undesirable material from the parenteral medicament fluid, and processing the desirable material.
  • parenteral medicament fluids including those having lipid-based constituents, emulsions, and/or drugs, may be processed to remove biological and/or particulate contaminants from the desirable components of the parenteral medicament fluid.
  • the processes and systems of the present invention also provide for removal of gas from the assembly and the parenteral medicament fluid.
  • Figure 1 is a bottom plan view of a parenteral medicament fluid processing device according to the invention.
  • Figure 2 is a top plan view of the device of Figure 1.
  • Figure 3 is a longitudinal sectional view taken along the line III-III of the device of Figure 1.
  • Figure 4 is a cross-sectional view taken along the line IV-IV of the device of Figure 1.
  • Figure 5 is a longitudinal sectional view taken along the line III-III of the device of Figure 1.
  • Figure 6 is a cross-sectional view taken along the line IV-IV of the device of Figure 1.
  • Figure 7 is an embodiment of a parenteral medicament fluid processing system according to the invention.
  • the present invention provides a method for treating a parenteral emulsion-containing medicament fluid comprising passing a parenteral emulsion- containing medicament fluid to a fluid filtration element, blocking microorganisms and other undesirable material, and passing the parenteral emulsion-containing medicament fluid therethrough.
  • the present invention also provides a device for treating a parenteral emulsion-containing medicament fluid comprising a fluid filtration element having a microorganism blocking pore rating wherein the fluid filtration element permits the parenteral emulsion-containing medicament fluid to pass therethrough, but blocks microorganisms and other undesirable material.
  • the present invention also involves a system for treating and administering a parenteral emulsion-containing medicament fluid comprising a parenteral emulsion-containing medicament fluid container in fluid communication with a filter assembly including a fluid filtration element which permits the parenteral emulsion-containing medicament fluid to pass therethrough, but blocks microorganisms and other undesirable material.
  • the present invention may also provide processes and systems for separating gas from the parenteral emulsion-containing medicament fluid and/or from the filter assembly or system.
  • a parenteral medicament fluid refers to a liquid-based solution or suspension having a medicament, preferably a drug, suitable for administration by means of a non-oral route.
  • Medicament refers to a medicinal agent or any substance used in a therapeutic regimen.
  • the medicament is a drug or the like.
  • the medicament may be soluble in water, but is preferably non-soluble in water.
  • Non-soluble medicament fluids typically include emulsions, preferably oil-in-water emulsions, and may include amphilic molecules such as lipids.
  • the parenteral medicament fluid may include an emulsion, a solution or a suspension including lipid substances, which are soluble in organic solvents, but are non-soluble, or slightly soluble, in water.
  • lipids include fatty acids, such as palmitic acid and linoleic acid; triglycerols ( ⁇ lso known as neutral fats) , such as tristearin; glycerophospholipids, such as phosphatidic acid or lecithin; sphingolipids, such as gangliosides; and steroids, such as cholesterol. It is intended that the present invention is not to be limited by the number, amount, or type of these substances.
  • the medicament fluids of the present invention may also include any of a number of other substances, including, but not limited to, emulsifying agents, such as phospholipids and the like; stabilizers; vasoconstrictive agents; nutrients, amino acids, electrolytes, trace elements, and vitamins. It is intended that the present invention is not to be limited by the number, amount, or type of these other substances.
  • the parenteral medicament fluid may also include a number of undesirable materials. The undesirable elements may be present in the fluid as a result of the storage condition or environment, normal metabolic processes, or due to the processing environment, or other causes.
  • undesirable material refers to microorganisms, e.g., bacteria and/or fungi, as well as particulate, chemical, and other biological substances which are preferably removed or depleted from the parenteral medicament fluid.
  • exemplary undesirable materials include but are not limited to particulates, and the like, typically, but not limited to coalesced particles, precipitates, pyrogenic matter such as bacterial endotoxins, administration set contaminants such as ampule and vial material, e.g., glass shards, septa bits, and the like. It is intended that the present invention is not to be limited by the type of undesirable material removed.
  • a parenteral emulsion-containing medicament fluid processing apparatus 10 generally comprises a housing 11, preferably transparent, having an inlet 15 and an outlet 19, and defining a fluid flow path between the inlet and the outlet.
  • the housing 11 may include an inlet 15 and an outlet 19 defining a vad flow path between the inlet 15 and the outlet 19 with the fluid filtration element 12 disposed across the fluid flow path.
  • the inlet 15 may communicate with a first chamber 16 which is in fluid communication with the fluid filtration element 12 as well as with at least one, more preferably, at least two gas venting elements 17 and 18 for removing gas and the like from the parenteral emulsion-containing medicament fluid and the housing 11.
  • the housing 11 may have interior walls 20 and 21 which, in combina- tion with the exterior walls for the housing 11, the gas venting elements 17 and 18, and the fluid filtration element 12, may define three additional chambers 22, 23, and 24.
  • Chambers 22 and 24 may include gas vents or outlets 25 for venting to the atmosphere gas separated from and/or displaced by, the incoming fluid.
  • the fluid filtration element 12 typically comprises a porous medium which permits an emulsion and a medicament to 5 pass therethrough, but blocks microorganisms and other undesirable material.
  • the fluid filtration element 12 may comprise a porous medium having a
  • the fluid filtration element 12 may comprise a porous medium having multiple layers, 13, 14, 30, 40, and 50.
  • the parenteral emulsion-containing medicament fluid processing apparatus 10 may also include at least one, and more preferably, at least two gas venting elements 17 and 18 positioned within the housing 11, to permit gas and the like to pass
  • Gas in the housing passes through venting elements 17 or 18 through at least one gas vent or outlet 25 for removing gas from the housing 11.
  • a parenteral emulsion-containing medicament fluid administration system according to the invention, as shown in Figure 7, generally comprises at least one container in fluid communication with a
  • parenteral emulsion-containing medicament fluid processing assembly which includes a fluid filtration element according to the invention.
  • Figure 7 shows an exemplary administration system including a parenteral emulsion-containing
  • Administration set 280 may include at least one container such as syringe 200, and fluid processing apparatus 10B.
  • container 200 is in fluid communication with parenteral 5 emulsion-containing medicament fluid processing assembly 10B through conduit 210.
  • the illustrated embodiment shows clamp 220 for controlling and/or directing the flow of parenteral emulsion-containing medicament fluid through the system, but other means
  • the administration system may also include at least one flow control device, e.g., pump 240, and additional clamps.
  • the fluid filtration element 12 in accordance with the present invention, comprises at least one porous medium suitable for passing a parenteral
  • the fluid filtration element may allow desirable components, such as lipids, which are typically about .5 micrometers or less in
  • the fluid filtration medium may also remove smaller material such as other microorganisms (e.g., bacteria), pyrogenic
  • the porous medium which is preferably microporous, may have a substantially uniform pore size or may include a pore size that varies in a continuous, discontinuous, or stepwise manner.
  • the porous medium has a pore size sufficient to block microorganisms and other undesirable substances, e.g., less than about 1.2 micrometers, preferably, less than about .8 micrometers, more preferably, less than about .5 micrometers, even more preferably, in the range of from about .2 to about .45 micrometers.
  • the fluid filtration element may have a single pore rating.
  • the fluid filtration element includes a pore rating sufficient to block microorganisms and other undesirable substances, e.g., less than about 1.2 micrometers, preferably, less than about .8 micrometers, more preferably, less than about .5 micrometers, even more preferably, in the range of from about .2 to about .45 micrometers.
  • Pore rating refers to the removal rating of a filtration element or porous medium in terms of measuring its efficiency in removing uniform and/or known substances, e.g., uniform diameter polystyrene icrospheres in a liquid medium.
  • the pore rating may be determined using a Latex Sphere Test.
  • a dilute suspension of spheres (0.01 to 0.1 weight percent) is prepared in water containing 0.1 weight percent Triton X-100, an octyl phenoxypolyeth xyethanol with about nine and one- half ethylene oxide units per molecule, available from Rohm & Haas Company.
  • the size of the spheres typically varies from about 0.038 to about 5 mi ⁇ crons. They are commercially available from Dow Chemical Company.
  • a volume of about 10 cubic centimeters of the suspension per square inch (of the iltration medium) is passed through the medium and the filtrate is collected in a test tube.
  • the concentration of microspheres in the filtrate can be measured by any number of means, for example, visually, or by use of a nephelometry device (i.e., turbidity meter) .
  • the fluid filtration element may comprise a porous medium including a single layer.
  • layer 60 may include a microorganism blocking pore rating, typically about 1.2 to about 0.1 micrometers.
  • a fluid filtration element according to the invention may also include a porous medium having multiple layers, i.e., two or more layers, and/or may include multiple porous media.
  • the different layers and/or media may include different pore sizes or ratings.
  • the fluid filtration element may include different pore sizes and/or layers, or the porous media within the fluid filtration element may have different pore sizes, ratings and/or layers, to enhance the filtration. While the mechanism is not well understood, it is believed the filtration may reflect non-permanent deformation of the emulsion as it passes through the fluid filtration element, allowing it to pass through pores that are smaller then the emulsion's normal diameter.
  • the emulsion may regain its normal shape and diameter without loss of its desirable characteristics.
  • Different pore sizes and/or pore ratings may enhance filtration, e.g., by progressively deforming the components of the emulsion as they pass through the element, and/or by preventing all of the components of the emulsion from passing through a given pore at the same time, which could restrict flow.
  • the fluid filtration element may comprise at least two layers, wherein the upstream layer has a coarser rating than the downstream layer, wherein at least the downstream pore rating blocks microorganisms and other undesirable material.
  • the fluid filtration element may also have an intermediate layer with a coarser pore rating than the upstream layer pore rating.
  • the layers Preferably, in those embodiments comprising at least two layers, the layers have different pore sizes and/or ratings, although the overall pore rating ranges for individual layers may overlap.
  • the fluid filtration element 12 may comprise a first most upstream layer 13 which may include a pore rating from about 5 to about 1 micrometers, which may be a coarser pore rating than the fifth, most downstream layer 50, which may include a finer, microorganism blocking pore rating of about 1.2 to about 0.1 micrometers.
  • Intermediate layer 40 may include a pore rating of about 50 to about 1 micrometers, and have a coarser pore rating than the most upstream first layer 13.
  • Other inner layers, here shown as second layer 14 and third layer 30, may have finer pore ratings than first layer 13.
  • second layer 14 may include a pore rating from about 3 to about .45 micrometers
  • third layer 30 may include a pore rating from about 1.2 to about .2 micrometers.
  • the selection of pore sizes, ratings and/or layers may be based on achieving a desired result, e.g., a low pressure drop.
  • the fluid filtration element may be produced from any suitable material compatible with a parenteral emulsion-containing medicament fluid, including commercially available materials.
  • the liquid filtration element of this invention may be preferably formed, for example, from any natural or synthetic material capable of forming fibers or a membrane.
  • Suitable polymers include, but are not limited to, polyolefins, polyesters, polya ides, polysulfones, acrylics, polyacrylonitriles, polyaramides, polyarylene oxides and sulfides, and polymers and copolymers made from halogenated olefins and unsaturated nitriles.
  • PVDF polyvinylidene difluoride
  • PBT polybutylene terephthalate
  • PET polyethylene terephthalate
  • nylon e.g.. Nylon 6, 11, 46, 66, and 610.
  • Preferred polymers are polyolefins, polyesters, and polyamides. Especially preferred are nylon and PBT.
  • suitable materials include cellulosic derivatives, such as cellulose acetate, cellulose propionate, cellulose acetate-propionate, cellulose acetate-butyrate, and cellulose butyrate.
  • Non- resinous materials such as glass fibers, may also be used.
  • Exemplary membranes are disclosed in U.S. Patent Nos. 4,906,374.
  • Other membranes including those disclosed in U.S. Patent Nos. 4,886,836; 4,964,989; 5,019,260; 4,340,479; 4,855,163; 4,774,132; 4,702,840; 4,707,266; 4,203,848 and 4,618,533, may also be suitable.
  • LOPRODYNE® membranes
  • HDC® fibrous media
  • membranes such as those available from Pall Corporation under the trademarks ULTIPOR N ⁇ ®, ULTIPOR®, FLUORODYNE®, POSIDYNE®, CARBOXYDYNE®, IMMUNODYNE®, BIODYNE A®, BIODYNE B®, and BIODYNE C®, may also be suitable.
  • the membrane may comprise a microporous membrane, more preferably a skinless microporous membrane.
  • a microporous membrane refers to a thin sheet, generally formed from a synthetic plastic material, having a substantially uniform, continuous matrix structure containing myriad pores typically ranging from a few micrometers to about 0.04 micrometers in diameter.
  • the fibrous medium may comprise a fibrous matrix, more preferably, a icrofibrous matrix.
  • a microfibrous matrix indicates a sheet-like web, or a three-dimensional network of fibers, whether melt-blown, staple, or continuous, which together form a coherent structure suitable for use as a filter medium.
  • Preferred microfibrous matrices are made from melt-blown ther ⁇ moplastic polymeric fibers, where the fiber diameter is typically in the range of from about 0.5 to about 20 micrometers, more preferably in the range of from about 1 to about 4 micrometers.
  • the fibrous medium comprises a synthetic, polymeric microfibrous matrix.
  • a microfibrous matrix may be more resistant to pressure build up and clogging. Additionally, a microfibrous matrix may be preferred because of its enhanced dirt capacity when compared to a microporous membrane. Moreover, a microfibrous matrix may enhance the deformation of the desirable component, e.g., a lipid particle, as the component passes through the microfibrous matrix. This deformation may be desirable in enhancing the material's ability to pass through a fine pore. Finally, the microfibrous matrix may enhance filtration by acting as a spacer. For example, in those embodiments including a membrane layer downstream of the microfibrous matrix layer, the spacer effect may prevent all of the particles from contacting the upstream surface of the membrane at the same time, which could restrict flow through the membrane.
  • the fluid filtration element may remain untreated, or the fibers or membrane may be treated to increase its effectiveness.
  • the fibers and/or the membrane may be surface modified to provide a low affinity for amide or peptide group-containing materials, particularly proteinaceous materials.
  • the fibers and/or the membrane may be surface modified to affect the critical wetting surface tension (CWST) of the element.
  • the fibers and/or membrane may be modified with a charge modifying agent to produce a negatively or positively charged medium, and/or a negative or positive zeta potential.
  • the fibers and/or the membrane are charge neutral.
  • a fiber and/or membrane can be modified by chemical reaction including wet or dry oxidation, by coating or depositing a polymer on the surface, or by a grafting reaction. Grafting reactions may be activated by exposure to an energy source such as gas plasma, heat, a Van der Graff generator, ultraviolet light, or to various other forms of radiation, or by surface etching or deposition using a gas plasma treatment.
  • the preferred method for a grafting reaction uses gamma-radiation, for example, from a cobalt source.
  • the preferred method for gas plasma treatment uses a low temperature gas plasma. More preferably, the gas plasma is an inorganic gas, for example, oxygen.
  • An exemplary technique for gas plasma treatment may employ at least one of an inorganic and organic gas, which may be a vaporized organic material such as an ethylenic monomer to be plasma polymerized or deposited on the surface of the substrate (e.g., the fibers and/or membrane).
  • a typical technique e.g., radio frequency (RF) discharge, involves placing a substrate to be gas plasma treated in a vacuum chamber and bleeding gas at low pressure into the system until the desired gas pressure differential is obtained.
  • An electromagnetic field may be generated by stibjecting the gas to a capacitive or inductive RF electrical discharge. The gas absorbs energy from the electromagnetic field and ionizes, producing high energy particles.
  • the resultant plasma modifies the fibers or medium in the plasma zone.
  • Inorganic gases suitable for use in gas plasma treatment may be exemplified by helium, argon. nitrogen, neon, nitrous oxide, nitrogen dioxide, oxygen, air, ammonia, carbon monoxide, carbon dioxide, hydrogen, chlorine, hydrogen chloride, bromine cyanide, sulfur dioxide, hydrogen sulfide, xenon, krypton, and the like.
  • Suitable organic gases may be exemplified by acetylene, pyridine, gases of organosilane compounds and organopolysiloxane compounds, fluorocarbon compounds and the like.
  • the fibers and/or membrane may be treated to modify the CWST of the fluid filtration element.
  • the fibers and/or membrane may be subjected to radiation or a plasma stream in the presence of an acrylic monomer such as hydroxethyl methacrylate (HEMA) or hydroxypropyl acrylate (HPA) to increase the CWST of the element.
  • HEMA hydroxethyl methacrylate
  • HPA hydroxypropyl acrylate
  • the fluid filtration element according to the invention includes a CWST in the range of about 30 dynes/cm to about 115 dynes/cm.
  • the fluid filtration element is hydrophilic, i.e., having a CWST greater than 72 dynes/cm.
  • the CWST may be in the range from about 75 to about 90 dynes/cm.
  • the CWST of a porous medium in units of dynes/cm, is defined as the mean value of the surface tension of the liquid which is absorbed and that of the liquid of neighboring surface tension which is not absorbed within a predetermined amount of time.
  • the absorbed and non-absorbed values depend principally on the surface characteristics of the material from which the porous medium is made and secondarily on the pore size characteristics of the porous medium.
  • the fluid filtration element may be surface modified by grafting thereon a hydroxyl-containing monomer to provide an element having a low affinity for amide or peptide-group containing materials, e.g., proteinaceous materials.
  • low affinity for proteinaceous materials refers to adsorption of less than about 100 micrograms per square centimeter of proteinaceous materials as measured by the Bovine
  • the adsorption of proteinaceous material is less than about 35 micrograms per square centimeter.
  • the fluid filtration element of this embodiment of the invention may be a polymeric substrate which may be surface modified using hydroxyl-containing unsaturated monomers, more typically monofunctional unsaturated monomers rich in pendant hydroxyl groups or groups capable of reacting to form hydroxyl groups, which are capable of undergoing polymerization and covalently bonding to the substrate under the influence of ionizing radiation.
  • Preferred monomers have moieties characterized by ethylenic or vinylic unsaturation and hydroxyl groups.
  • Preferred monomers include hydroxyalkyl acrylates in which the "alcoholic" or hydroxyl.- containing portion of the molecule (as opposed to the portion of the molecule "derived” from a carboxylic acid) constitutes a substituted lower alkyl group having from 2 to 5 carbon atoms, preferably from 2 to 3 carbon atoms. The substituent is preferably a hydroxyl group. Mixtures of monomers may also be used.
  • the most preferred hydroxyl-containing monomers are those in which the hydroxyl group is pendant, i.e., the group is not attached to a carbon atom which forms part of the polymer's backbone but is bound to a carbon atom that is separated from the backbone as, for example, a branching carbon atom.
  • Exemplary preferred monomers include 2-hydroxyethyl acrylate, 2- hydroxyethyl methacrylate, 3-hydroxypropyl acrylate, and 3-hydroxypropyl methacrylate, which may be commercially available from, for example, Rohm and Haas Chemical Company under the trademark ROCRYL®.
  • suitable monomers may also be further characterized by their properties, such as responding to ionizing radiation by forming a free radical.
  • Suitable monomeric compounds should be substantially completely, if not totally, soluble in the solvents used.
  • Preferred solvents include polar solvents, particularly hydroxylated solvents such as water, lower aliphatic alcohols, such as ethanol, and mixtures thereof.
  • Solutions of the monomer compound may range in concentration of the monomer(s) from about 0.1 to about 5.0 percent, by weight, preferably about 0.2 to about 3.0 percent, by weight, based on the total weight of the solution.
  • the procedure used to saturate the porous polymeric support is known to one of skill in the art. For example, batch or continuous processes may be suitable. After saturation, the monomer(s) may be polymerized and covalently bound to the polymeric substrate under the influence of ionizing radiation, more preferably, gamma radiation or short wavelength ultraviolet radiation.
  • the fluid filtration element may be fashioned in a variety of ways. For example, it may include one or more of the following: a web, a sheet, and a depth filter.
  • the fluid filtration element may be formed into any geometric shape or form suitable for passing a parenteral emulsion-containing medicament fluid therethrough.
  • the fluid filtration element comprises at least one flat planar sheet, although in a less desirable embodiment, it may comprise at least one sheet formed into a pleated, corrugated, or accordion form.
  • the fluid filtration element which may be fibrous and/or membranous, may comprise a composite or a multilayer arrangement. Layers may be individually prepared and bonded together by various means known to those skilled in the art. Layers may be contiguous and/or separate. The fluid filtration element may be preformed to form an integral unitary structure. The fluid filtration element may also include additional constituents, including, but not limited to at least one layer to provide support and/or better drainage. Exemplary supports and/or drainage components are non-woven polyester or polypropylene mesh.
  • the layers or porous media which constitute the fluid filtration element may be arranged in a variety of ways with respect to fluid flow.
  • a fibrous medium may be interposed between at least one upstream membrane and at least one downstream membrane.
  • the fluid filtration element may comprise three upstream membrane layers, followed by the fibrous layer and the downstream membrane.
  • the membrane layers may have decreasing pore ratings in the upstream to downstream direction.
  • the fibrous layer may have a coarser pore rating than at least one of the upstream membrane layers.
  • the fluid filtration element of devices made in accordance with this invention may be preformed to controlled dimension and pore size and/or rating in order to form an integral, self-contained element prior to assembly in a housing.
  • Preforming eliminates the pressure on the inlet and outlet faces of the container which may be inherent, e.g., in a packed fiber system.
  • Pre-forming the element typically leads to devices having longer service life, coupled with better removal of undesirable material and less hold up of fluid, when compared to devices that use fibers or fibrous webs packed in a housing at assembly.
  • a fluid filtration element produced in accordance with the present invention for passing parenteral emulsion-containing medicament fluid preferably may have a flow area of about .65 cm 2 to about 929 cm 2 (about .1 to about 144 in 2 ) , more preferably in the range from .65 cm 2 to about 97 cm 2 (about .1 to about 15 in 2 ) .
  • the term low area refers to the face surface area contacted by the parenteral emulsion-containing medicament fluid.
  • a preferred relative voids volume may be in the range of about 50% to about 90%, more preferably in the range of from about 60% to about 85%.
  • the thickness of the fluid filtration element may be in the range of from about .008 cm to about .25 cm (about 0.003 inches to about 0.100 inches) , more preferably in the range of from about .013 cm to about .25 cm (about 0.005 to about 0.100 inches).
  • the fiber surface area of the fluid filtration element may be in the range of from about .2 to about 2.5M 2 /g, preferably from about .5 to about
  • the element area may be adjusted as necessary.
  • a filter device of the subject invention may include at least one, and more preferably, two, gas venting elements 17 and 18, each comprising at least one porous medium which is liquid-repellant or non- wettable by the parenteral emulsion-containing medicament fluid and which allows gas that may be present in the parenteral emulsion-containing medicament fluid and the assembly to pass out of the device, for example, through vent 25.
  • the gas venting element comprises at least one microporous membrane. .
  • the gas venting element may vent gas from the system, in order to prime the device and eliminate any extraneous gas. This may be desirable since the presence of gas may reduce the efficiency of the fluid filtration element, e.g., by blocking the filtration element.
  • the gas venting element may prevent gas from being administered, e.g., to a patient.
  • gas refers to any gaseous fluid, such as air, sterilized air, oxygen, carbon dioxide, and the like; it is intended that the invention is not to be limited thereby.
  • the gas venting element may be oriented in a variety of ways with respect to the flow of the parenteral emulsion-containing medicament fluid.
  • the gas venting element may be located in any of the various components of the filter assembly or the administration system.
  • at least one gas venting element may be included in at least one of the conduits used to connect the various components of the administration system, in a wall of a container, or in a port on or in one of the containers or the filter assembly.
  • the gas venting element should have the necessary strength to handle the pressures encountered in use and have the ability to provide the desired permeability without the application of excessive pressure.
  • the gas venting element may be produced from any suitable material which is compatible with the parenteral emulsion-containing medicament fluid, including commercially available materials.
  • the gas venting element may be formed, for example, from the materials listed above with respect to the liquid separation element.
  • Preferred polymers are polyolefins, polyesters, polyamides, polyurethanes, polysulfones, and fluoropolymers such as polyvinylidene difluoride, polytetrafluoroethylene, and perfluoroalkoxy resins. Particularly preferred are fluoropolymers, more preferably, polytetrafluoroethylene (PTFE) .
  • Exemplary gas venting elements include, but are not limited to, those disclosed in U. S. Patent Nos. 4,954,256, and 5,126,054; and International Publication Nos. WO 91/17809 and WO 92/07656.
  • the gas venting element may be untreated, or treated or modified to make it more effective.
  • the element may be liquophobic.
  • a liquophobic gas venting element in the context of this invention is one that has a critical wetting surface tension lower than the surface tension of the parenteral emulsion-containing medicament fluid, or is not readily or spontaneously wetted by the parenteral emulsion-containing medicament fluid. Because the liquophobic element is not wettable, or poorly wettable, by the parenteral emulsion-containing medicament fluid being treated or processed in the system, gas in the system that contacts the liquophobic medium may pass through it, while the parenteral emulsion-containing medicament fluid may not.
  • the gas venting element may be treated to increase its liquophobicity.
  • the element may be surface modified to decrease the critical wetting surface tension (CWST) , with the term CWST being as defined above with respect to the fluid filtration element.
  • CWST critical wetting surface
  • the gas venting element may have a CWST of less than about 28 dynes/centimeter, rendering it liquid-repelling or non-wetting by liquids with surface tensions well below that of water's surface tension of 72 dynes/centimeter.
  • Surface characteristics of the gas venting element may be modified by a number of methods, including those described above with respect to the fluid filtration element.
  • the element may comprise an untreated PTFE microporous membrane commercially available from, for example, W. L. Gore Associates, Inc.
  • the element may be surface modified by bonding thereon one or more fluorine-containing monomers.
  • a porous structure preferably a microporous, polymeric membrane comprising a fluoropolymer substrate, more preferably a poly(vinylidene fluoride) membrane substrate
  • a solution comprising one or more polymerizable fluorine- containing monomers containing an ethylenically unsaturated group and a fluoroalkyl group in a suitable solvent, and exposed to gamma radiation to form a superstrate fluoropolymer chemically bonded to the membrane.
  • the selected pore rating of the gas venting element may effectively preclude wetting at the operating, pressures utilized for processing the parenteral emulsion-containing medicament fluid.
  • a gas venting element having a pore rating of about 0.02 micrometers operated in a typical administration system may vent gas without passing parenteral emulsion-containing medicament fluid therethrough.
  • the gas venting element may be open to the atmosphere to allow the gas to be vented, which could allow bacteria to enter, the pore rating should be about 0.3 micrometers or less, more preferably in the range of about 0.2 to about .02 micrometers, to 5 preclude bacteria from entering either the system or the parenteral emulsion-containing medicament fluid.
  • the gas venting element may include a plurality (i.e., two or more) of layers.
  • the element may include additional constituents, including, but not
  • liquophilic refers to a medium that has a critical wetting surface tension higher than the surface tension of the parenteral emulsion-containing
  • the layers of the gas venting element may be individually prepared and bonded together by
  • the fluid filtration element 12, with or without the gas venting element 17 and 18, may be positioned across the parenteral emulsion-containing medicament fluid flow path within a housing 11
  • the parenteral medicament fluid filter assembly may comprise any housing containing a fluid filtration element suitable for passing emulsion and medicament therethrough, but blocking microorganisms
  • the housing may be fabricated from any suitably rigid, impervious material, including any impervious thermoplastic material, which is compatible with the fluid being processed.
  • the housing may be fabricated from any suitably rigid, impervious material, including any impervious thermoplastic material, which is compatible with the fluid being processed.
  • the housing may be fabricated from any suitably rigid, impervious material, including any impervious thermoplastic material, which is compatible with the fluid being processed.
  • the housing may be fabricated from any suitably rigid, impervious material, including any impervious thermoplastic material, which is compatible with the fluid being processed.
  • the housing may be fabricated from any suitably rigid, impervious material, including any impervious thermoplastic material, which is compatible with the fluid being processed.
  • the housing may be fabricated from any suitably rigid, impervious material, including any impervious thermoplastic material, which is compatible with the fluid being processed.
  • the housing may be fabricated from any suitably rigid, impervious material, including any impervious thermoplastic material, which is compatible with the fluid
  • the housing 35 be fabricated from a metal, such as stainless steel. or from a polymer.
  • the housing is fabricated by injection molding from a polymer, more preferably a transparent or translucent polymer, such as an acrylic, polypropylene, polystyrene, or a polycarbonated resin.
  • the housing may be diethylhexylphthalate (DEHP) free and/or phthalate free.
  • DEHP diethylhexylphthalate
  • the housing may include an arrangement of one or more channels, grooves, conduits, passages, ribs or the like which may be serpentine, parallel or curved, or a variety of other configurations to provide for more efficient flow of parenteral emulsion-containing medicament fluid and/or gas.
  • the surfaces of the housing contacting the fluid may be treated or untreated.
  • the surfaces of the housing contacting the fluid may be rendered liquophilic for better priming.
  • Methods for treating the surface of the housing include but are not limited to radiation grafting and gas plasma treatment.
  • Any housing of suitable shape to provide an inlet, an outlet, and an adequate flow area may be employed.
  • the filter assembly in accordance with this invention may be f shioned in a variety of configurations including, but not limited to, those described in U. S. Patent 3,803,810.
  • the filter assembly may have a hold up volume of about 50 milliliters or less.
  • Preferred configurations, as depicted in Figures 1- 6, can be constructed with a hold up volume of less than about 40 milliliters, more preferably, less than about 25 milliliters; or with a hold up volume of less than about 5 milliliters, more preferably, less than about 2 milliliters.
  • All of the components of the filter assembly may be variously configured with respect to parenteral emulsion-containing medicament fluid flow.
  • the inlet 15 may be configured as a spike which can be inserted into a container of parenteral emulsions-containing medicament fluid.
  • both the inlet and the outlet can be configured as tube connectors.
  • the chambers may be configured in a variety of ways, e.g., to maximize fluid contact with the fluid filtration element, minimize hold up volume, and/or decrease the pressure drop.
  • gas venting element may be located in a separate housing or conduit, with or without at least one of the following: a chamber; a gas vent or outlet; a cap; and a clamp.
  • the fluid filtration element may be sealed or fit within the housing to achieve convenience of use, rapid priming, and efficient air clearance. Suitable techniques for sealing or fitting the medium within the housing are known to those skilled in the art.
  • the fluid filtration assembly in accordance with the invention may be fashioned to operate at the range of pressures encountered in use.
  • the fluid filtration assembly typically operates at pressures of less than about 25 psi, more preferably less than about 15 psi, and even more preferably, less than about 10 psi.
  • the volumetric capacity of the assembly may vary.
  • a typical volumetric capacity for a parenteral emulsion- containing medicament fluid such as an anesthetic may be less than about 1 liter, more preferably, in the range of from about 2 or about 3 milliliters to about 500 milliliters.
  • the ilter assembly may be incorporated into a parenteral emulsion-containing medicament fluid processing and/or administration set.
  • the containers 200 which may be used in the parenteral emulsion-containing medicament fluid administration set may be constructed of any material compatible with a parenteral emulsion-containing medicament fluid.
  • the composition of the container may vary on the nature of the parenteral emulsion-containing medicament fluid or fluids utilized.
  • the container may be DEHP free and/or phthalate free.
  • a wide variety of suitable containers are already known in the art.
  • container 200 may be composed of a flexible material, for example, polyvinyl chloride (PVC) .
  • the containers may be composed of a non-flexible material, for example, polypropylene, acrylonitrile butadiene styrene (ABS) , polycarbonate, or stainless steel.
  • Exemplary containers include a syringe or a flexible bag. It is intended that the invention should not be limited by the type or composition of the container being employed.
  • the conduits 210 may be constructed of any material that is compatible with the parenteral medicament fluid, preferably PVC.
  • the conduits may be DEHP free and/or phthalate free.
  • the conduits are any tubing or means which provideizid communication between the various components of the administration set.
  • a clamp, seal, stopcock, valve, transfer leg closure, or the like may be in fluid communication with at least one of the conduits in order to facilitate a desired function, i.e., establishing a desired flow path for parenteral medicament fluid and/or gas.
  • the parenteral medicament fluid administration set may have components such as, but not limited to, additional containers, means to provide fluid communication and/or establish a desired flow path, and injection ports.
  • the invention also includes methods for treating and administering a parenteral emulsion- containing medicament fluid comprising passing an emulsion-containing medicament fluid to a fluid filtration element, blocking microorganisms and other undesirable material, and passing desirable components of the parenteral medicament fluid therethrough.
  • a method according to the invention may also include passing gas present in the filter assembly and/or in the parenteral medicament fluid through a gas venting element, and blocking the parenteral medicament fluid from passing therethrough.
  • a method may also include further processing the treated parenteral medicament fluid by administering it to a patient.
  • Parenteral medicament fluid may be passed through the fluid filtration element and administered for any length of time. Accordingly, fluid may be administered over a short period of time, e.g., to provide a bolus dose for several minutes, or fluid may be administered over a long period, e.g., to provide a sedative dose over several days. The administration of a sedative dose over several days may be particularly advantageous when the patient has suffered serious injury, e.g., head trauma.
  • a method according to the invention may include passing a parenteral emulsion-containing medicament fluid into filter assembly 10 via the inlet 15, and, as depicted by the arrows in Figure 3, into chamber 16.
  • the parenteral medicament fluid then passes through the fluid filtration element 12 into chamber 23, and passes out of the filter device 10 via the outlet 19.
  • Passing the medicament fluid through the fluid filtration element may include blocking microorganisms and other undesirable substances from passing therethrough.
  • Passing gas present in the parenteral medicament fluid and/or the filter assembly may include passing gas into the chamber 16 and, as depicted by the arrows in Figure 4, passing the gas freely through the gas venting elements 17 and 18 into the chambers 22 and 24 and out the gas outlets or vents 25.
  • An exemplary method may also include treating a parenteral emulsion-containing medicament fluid by passing it through an administration system wherein the parenteral medicament fluid in a container is passed from the container through a conduit and a filter assembly which includes a fluid filtration element. Passing the parenteral emulsion-containing medicament fluid through the fluid filtration . element may include blocking microorganisms and other undesirable material.
  • clamp 220 is opened, and a pressure differential is created, e.g., by depressing the plunger on syringe 200, such that parenteral emulsion-containing medicament fluid passes from the container 200, through conduit 210, and through the filter assembly 10B.
  • a pressure differential is created, e.g., by depressing the plunger on syringe 200, such that parenteral emulsion-containing medicament fluid passes from the container 200, through conduit 210, and through the filter assembly 10B.
  • gas ahead of the fluid may be passed out of the filter assembly 10B through vents 17 and 18 and outlets 25.
  • desirable components of the parenteral emulsion-containing medicament fluid pass through the fluid filtration element within the assembly, while microorganisms and other undesirable material are blocked.
  • the filtered medicament fluid then passes out of the filter assembly 10B, through conduit 210, and into another container or into the patient.
  • a flow control device e.g., a pump 240, more preferably an infusion pump, even more preferably an infusion pump with at least one occlusion alarm (not shown) located either upstream or downstream of the filter assembly may be used to control the flow rate during administration. It is intended that the present invention is not to be limited by the use or type of flow control device.
  • Flow rates of the fluid may range from about several milliliters per hour to about 2000 milliliters per hour, as desired.
  • a typical flow rate for a parenteral emulsion-containing medicament fluid may be from about 60 milliliters per hour to about 2000 milliliters per hour.
  • passing the parenteral emulsion-containing medicament fluid through the fluid filtration element 12 removes microorganisms and other undesirable material from the parenteral emulsion-containing medicament fluid with a pressure drop of about 20 psi or less, preferably about 15 psi or less, and even more preferably, 10 psi or less while passing the par ⁇ enteral emulsion-containing medicament fluid at a flow rate of up to about 1200 milliliters per hour.
  • additional fluids, including parenteral medicament fluids may be introduced into the system through other components of the administration set, e.g., injection ports and/or connectors located upstream and/or downstream of the filter assembly.
  • gas may be separated from the parenteral emulsion-containing medicament fluid through a gas venting element that does not act in concert with the fluid filtration element.
  • gas venting element may be located downstream, or, more preferably, upstream, of the filter assembly, e.g., in a separate housing located in coniuit 210.
  • the venting element may be located upstream of the filter assembly, and a clamp 220 located between the filter assembly and the venting element may be closed, so that creating a pressure differential causes gas displaced by the parenteral emulsion-containing medicament fluid to pass through the venting element. Once the gas has been displaced, the clamp may be opened.
  • the gas venting element may include an additional liquophilic layer (preferably upstream of the liquophobic layer) that, once wetted, precludes the entrance of air.
  • the configuration of the housing including the gas venting element may provide for capping and uncapping the gas venting element as desired. Examples
  • the filter assemblies used in the following Examples were primed before testing as follows: A 60 cc syringe was filled with a parenteral emulsion- containing medicament fluid. The filter assembly was held above the level of the syringe, and, while holding the assembly with the outlet facing up, the plunger of the syringe was manually depressed, causing the parenteral emulsion-containing medicament fluid to flow through the assembly, while gas flowed through the venting element and exited from the assembly. The housing was tapped gently to dislodge air bubbles. Once primed, the filter assembly was tested as noted below.
  • DIPRIVAN® (Stuart Pharmaceuticals) , which is a hypnotic agent for use in the induction and maintenance of anesthesia.
  • DIPRIVAN® includes propofol in an oil- in-water emulsion which also includes soybean oil, glycerol, lecithin and sodium hydroxide.
  • Propofol is chemically described as 2,6-diisopropylphenol, with a molecular weight of 178.27.
  • Example 1 A filter assembly having a housing, a fluid filtration element in the form of a flat microporous ULTIPOR N ⁇ ® membrane having a microorganism blocking pore rating as noted below, and a CWST of 76 ⁇ 4 dynes/cm, along with two gas venting elements, which were flat PTFE membranes (W. L. Gore Associates, Inc.), each having a nominal pore rating of about 0.02 micrometers and a CWST of 23 dynes/centimeter, was used in the three tests in this Example.
  • the fluid filtration element was a microporous ULTIPOR N ⁇ ® membrane, supported as disclosed in U. S. Patent No. 4,340,479, with a microorganism blocking pore rating of about 0.45 micrometers.
  • the fluid filtration element in the third test which had a microorganism blocking pore rating of 0.2 micrometers, was formed by co-drying two microporous ULTIPOR N ⁇ ® membranes, the upstream membrane having a pore rating of about 0.2 micrometers, and the downstream membrane having a pore rating of about 0.8 micrometers.
  • the fluid filtration element and gas venting elements were sealed in a housing to form a filter assembly as generally described with respect to Figures 1-6.
  • Tubing was connected from the outlet to a 50 ml graduated cylinder. Tubing was connected from the inlet to a 60 cc plastic syringe, with a 0-15 psi pressure gauge interposed in the tubing between the syringe and the inlet.
  • the syringe had been previously filled with 60 ml of DIPRIVAN®, and the filter assembly had been primed as noted above.
  • the syringe was mounted in a Harvard Apparatus Inc. programmable syringe pump (Model 44) . The Harvard pump was programmed to run at a bolus (or induction) rate of 20.0 ml/min for 20 ml of DIPRIVAN®, and operated according to the manufacturer's instructions. Three tests were performed, and the pressure was recorded during each test, with the following results:
  • Test 1 pore rating of about 0.45 micrometers
  • Test 2 pore rating of about 0.45 micrometers
  • Final pressure was about 9.3 psi
  • Test 3 pore rating of about 0.2 micrometers
  • Final pressure was about 12.0 psi.
  • Example 1 showed that fluid filtration elements having membranes with microorganism blocking pore ratings of about 0.45 and about 0.2 micrometers will pass a parenteral emulsion-containing medicament fluid therethrough at a bolus rate of 20.0 ml/min.
  • a filter assembly having a fluid filtration element with a microorganism blocking pore rating of about 0.45 micrometers was set up and tested as generally described with respect to Figure 1, with the exception that the Harvard pump was programmed to run at a maintenance rate of 1.0 ml/min for 20 ml of Diprivan®.
  • Example 2 showed that a fluid filtration element having a membrane with a microorganism blocking pore rating of about 0.45 micrometers will pass a parenteral emulsion-containing medicament fluid therethrough at a maintenance rate of 1.0 ml/min.
  • the filter assembly used in this example was set up and tested as in the previous examples, with the following exceptions: 1) the fluid filtration element was a LOPRODYNE® membrane having a microorganism blocking pore rating of about 0.45 micrometers and a CWST of 83 dynes/cm, and an adsorption of proteinaceous material as measured by the Bovine Serum Albumin Adsorption test of less than about 15 micrograms per square centimeter, and 2) the same filter assembly was tested at an induction rate of 20.0 ml/min for 20 ml of DIPRIVAN®, and then at a maintenance rate of 1.0 ml/min for 40 ml of DIPRIVAN®.
  • the results are listed below.
  • the first value i.e., at 20.0 ml
  • ml volume
  • pressure psi
  • Example 3 demonstrated that a fluid filtration element having a membrane which has a microorganism blocking pore rating of about 0.45 micrometers and a low affinity for amide-group containing materials will pass a parenteral emulsion-containing medicament fluid including a lipid emulsion therethrough, with less of a pressure drop than other membranes having similar microorganism blocking pore ratings. Furthermore, Example 3 demonstrated this at different rates, i.e., at a bolus rate of 20.0 ml/min, and at a maintenance rate of 1.0 ml/min.
  • the filter assembly used in this example was set up and tested as in Example 3, using an ULTIPOR N ⁇ ® membrane having a microorganism blocking pore rating of about 0.45 micrometers in a housing as - generally described in Example 1.
  • Examples 3 and 4 demonstrated that a fluid filtration element having a membrane with a microorganism blocking pore rating of about 0.45 micrometers will pass a parenteral emulsion- containing medicament fluid therethrough, but at a higher pressure drop than a similarly tested membrane which has a similar microorganism blocking pore rating but also has a low affinity for amide- group containing materials.
  • This Example compared the distribution of lipid particles in iltered DIPRIVAN® to unfiltered DIPRIVAN®.
  • the filter assembly included a LOPRODYNE® membrane having a microorganism blocking pore rating of about 0.45 micrometers as described in Example 3.
  • a 20 milliliter ampule of DIPRIVAN® was opened, and 5 ml of the emulsion was withdrawn and passed through the filter assembly described above and then through a dynamic light scattering (DLS) device (NICOMP Model 370) for sub icron particle size analysis. Another 5 ml of the emulsion was passed through the DLS device without passing it through a filter assembly.
  • DLS dynamic light scattering
  • Gaussian analyses revealed the mean diameter of the filtered particles was 202.2 nm (about .2. micrometers) , while the mean diameter of the unfiltered particles was 223.5 nm (about .22 micrometers) .
  • Example 5 demonstrated that a fluid filtration element having a membrane with a microorganism blocking pore rating of about 0.45 micrometers will pass the lipid emulsion therethrough without adversely affecting the distribution of the lipid particles.
  • the fluid filtration element used in this example was formed of five layers of flat discs, each having a nominal diameter of 47 mm and a surface area of about 17.35 cm 2 (2.69 in 2 ), which were placed in a jig, as described below. Going from the upstream to the downstream direction, the first three layers were LOPRODYNE® nylon membranes with nominal microorganism blocking pore ratings of 1.2 micrometers, 0.65 micrometers, and 0.45 micrometers, respectively, and each had a CWST of 83 dynes/cm. The next layer was an HDC® microfibrous PBT layer with a pore rating of about 30 micrometers, with the smooth side of the layer facing downstream.
  • the next layer was formed by co- drying two nylon ULTIPOR N ⁇ ® membranes, one having a microorganism blocking pore rating of about 0.2 micrometers and the other having a microorganism blocking pore rating of about 0.8 micrometers, as described in Example 1.
  • the 5 layers were clamped between the inlet and outlet halves of a housing jig, and the jig was connected to a 0-15 psi gauge, a 60 cc syringe, and a Harvard pump, and tested as generally described in Example 1, although the flow rate was 1.0 ml/min.
  • the fluid iltration element was set up and tested as in Example 6, except that the Harvard pump was programmed to run at a bolus rate of 20.0 ml/min for 20 ml of DIPRIVAN®. The pressure reached 14.9 psi.
  • parenteral emulsion-containing medicament fluids may be passed through fluid iltration elements including a number of layers having different pore ratings, and having a coarser pore rating upstream and a finer, bacterial removing (i.e., 0.2 micrometer) pore rating downstream, at a variety of flow rates, including a surge bolus rate, without excessive pressure build up, to produce a bacteria-depleted infusate. Additionally, Examples 6 and 7 demonstrated that parenteral medicament fluids may be passed through fluid filtration elements including layers having different microorganism blocking pore ratings.
  • Example 3 Two filter assemblies as described in Example 3 were challenged with Moraxella. in DIPRIVAN®, at flow rates of 20 ml/min and 1.5 ml/min, respectively, using a Sage Instruments Model 351 pump.
  • the input challenge to each assembly was a total of 4.8 x 10 5 organisms in each 20 ml of DIPRIVAN®. No organisms were recovered downstream.
  • Example 8 demonstrated that fluid filtration elements having microorganism blocking pore ratings of about 0.45 micrometers blocked the passage of Moraxella without clogging.
  • Example 3 Two filter assemblies as described in Example 3 were tested as generally described in Example 8, at a flow rate 20.0 ml/min, and challenged with Candida albicans.
  • the input challenge to each assembly was 0.48 x 10 4 cfu/ml x 20 ml, which resulted in 9.6 x 10 5 total organisms per filter. No organisms were recovered downstream.
  • Example 9 demonstrated that fluid filtration elements having microorganism blocking pore ratings of about 0.45 micrometers blocked the passage of Candida albicans without clogging.
  • Example 10 Two filter assemblies as described in Example 3 were tested as generally described in Example 8, at a flow rate of 20.0 ml/min, and challenged with Acinetobacter lwoffi in 20 ml of DIPRIVAN® containing either 4.8 x 10 5 or 5.3 x 10 5 total organisms. No organisms were recovered downstream.
  • Example 10 demonstrated that fluid filtration elements having microorganism blocking pore ratings of about 0.45 micrometers blocked the passage of Acinetobacter lwoffi without clogging.
  • Example 8 Two filter assemblies similar to those described in Example 1, each having a fluid filtration element formed from ULTIPOR N 66 ® membranes and having a microorganism blocking pore rating of about 0.2 micrometers, were tested as generally described in Example 8, at a flow rate of 20.0 ml/min, and challenged with Acinetobacter lwoffi in 20 ml of DIPRIVAN® containing 8.8 x 10 4 total organisms.
  • the filter assemblies allowed 3.5 ml of fluid to pass prior to pump failure unrelated to the function of the filter assembly. No organisms were recovered downstream.
  • Example 11 demonstrated that fluid filtration elements having microorganism blocking pore ratings of about 0.2 micrometers at least provide initial blockage of Acinetobacter lwoffi.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • External Artificial Organs (AREA)

Abstract

On traite un fluide de médicament à administration parentérale contenant une émulsion, en le faisant passer dans un ensemble à filtre (10). Le fluide est introduit par l'entrée (15) dans la chambre (16) et il est ensuite amené à traverser un élément de filtrage de fluide (12) pour aboutir dans la chambre (23), puis il sort du dispositif à filtre (10) par la sortie (19). Le passage du fluide à travers l'élément de filtrage (12) bloque les micro-organismes et toute autre substance indésirable en les empêchant de passer. Les gaz qui peuvent se trouver dans le fluide et/ou dans l'ensemble à filtre (10) peuvent être amenés à traverser des éléments évacuateurs de gaz (17, 18).
PCT/US1993/004021 1992-04-29 1993-04-28 Procede et dispositif pour traiter des fluides de medicaments a administration parenterale contenant une emulsion WO1993022029A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69326947T DE69326947T2 (de) 1992-04-29 1993-04-28 Methode und vorrichtung zur behandlung eines eine parenterale emulsion enthaltende medikamentfluidums
CA002132422A CA2132422C (fr) 1992-04-29 1993-04-28 Methode et dispositif pour traiter une solution medicamenteuse parenterale contenant une emulsion
EP93910894A EP0637986B1 (fr) 1992-04-29 1993-04-28 Procede et dispositif pour traiter des fluides de medicaments a administration parenterale contenant une emulsion
JP51950693A JP3169612B2 (ja) 1992-04-29 1993-04-28 非経口乳剤を含む医薬流体を処理する方法及び装置
GB9420642A GB2280860B (en) 1992-04-29 1993-04-28 Method and device for treating a parenteral emulsion-containing medicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/875,774 US5536413A (en) 1990-12-03 1992-04-29 Method for treating a parenteral emulsion-containing medicament fluid
US07/875,774 1992-04-29

Publications (1)

Publication Number Publication Date
WO1993022029A1 true WO1993022029A1 (fr) 1993-11-11

Family

ID=25366340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/004021 WO1993022029A1 (fr) 1992-04-29 1993-04-28 Procede et dispositif pour traiter des fluides de medicaments a administration parenterale contenant une emulsion

Country Status (7)

Country Link
US (1) US5536413A (fr)
EP (1) EP0637986B1 (fr)
JP (1) JP3169612B2 (fr)
CA (2) CA2074692A1 (fr)
DE (1) DE69326947T2 (fr)
GB (1) GB2280860B (fr)
WO (1) WO1993022029A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021644A1 (fr) * 1994-02-10 1995-08-17 Roland Wex Filtre a sang
US5622626A (en) * 1994-04-15 1997-04-22 Pall Corporation Multiple compartment filter and method for processing parenteral fluid
WO1997025084A1 (fr) * 1996-01-11 1997-07-17 Beth Israel Deaconess Medical Center Utilisation d'un filtre integre dans la preparation de melanges d'addition nutritifs entiers
EP1684716A1 (fr) * 2003-11-05 2006-08-02 The Australian National University Dispersions et leurs procedes de preparation
WO2007008629A2 (fr) * 2005-07-11 2007-01-18 Hewlett-Packard Development Company, L.P. Separation de liquides et de gaz d'avec des mousses
EP2314332A1 (fr) * 2009-10-21 2011-04-27 Gambro Lundia AB Système de délivrance de fluide médical
EP3444000A1 (fr) * 2012-03-29 2019-02-20 Saint-Gobain Performance Plastics Corporation Appareil filtre d'aiguille
US10568810B2 (en) 2012-03-29 2020-02-25 Saint_Gobain Performance Plastics Corporation Needle filter apparatus
WO2020160014A1 (fr) * 2019-01-29 2020-08-06 Donaldson Company, Inc. Système et procédé de désaération
DE102009045403B4 (de) 2009-10-06 2022-08-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung zum Trennen von Gas und Flüssigkeit und deren Verwendungen

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935092A (en) 1990-12-20 1999-08-10 Baxter International Inc. Systems and methods for removing free and entrained contaminants in plasma
US6010633A (en) * 1997-03-06 2000-01-04 Hemasure Inc. Method of preventing air from becoming entrapped within a filtration device
US5472605A (en) * 1994-03-10 1995-12-05 Hemasure, Inc. Filtration device useable for removal of leukocytes and other blood components
US6251292B1 (en) 1994-03-10 2001-06-26 Hemasure, Inc. Method of preventing air from becoming entrapped within a filtration device
US5798041A (en) 1995-09-06 1998-08-25 Hemasure, Inc. In-line liquid filtration device useable for blood, blood products or the like
US6190855B1 (en) 1996-10-28 2001-02-20 Baxter International Inc. Systems and methods for removing viral agents from blood
US6168718B1 (en) 1996-11-08 2001-01-02 Pall Corporation Method for purifying blood plasma and apparatus suitable therefor
US6689278B2 (en) * 1996-11-18 2004-02-10 Douglas K. Beplate Combined hydrophobic-hydrophilic filter for fluids
US6375854B2 (en) * 1996-11-18 2002-04-23 Douglas K. Beplate Combined hydrophobic-hydrophilic filter for fluids
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
WO1999043301A1 (fr) * 1998-02-24 1999-09-02 The Board Of Trustees Of The University Of Illinois Emulsions lipides pour le traitement de l'intoxication generale
US6967105B2 (en) * 2000-12-02 2005-11-22 Queststar Medical, Inc. Surface-modified wick for diagnostic test strip
US8283029B2 (en) * 2001-08-13 2012-10-09 Clopay Plastic Products Company, Inc. Multilayer microporous films and composites for barrier protective materials, and methods
TWI296571B (en) * 2001-08-13 2008-05-11 Clopay Corp Mulyilayer microporous films and methods
JP4405206B2 (ja) * 2003-08-08 2010-01-27 株式会社Ｒｏｋｉ 仕切り部材付きケース
ITMI20051826A1 (it) * 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
WO2007118235A2 (fr) * 2006-04-07 2007-10-18 Nxstage Medical Inc. Système de filtration pour la préparation de fluides pour applications médicales
US9750829B2 (en) 2009-03-19 2017-09-05 Emd Millipore Corporation Removal of microorganisms from fluid samples using nanofiber filtration media
EP2694196B1 (fr) 2011-04-01 2021-07-21 EMD Millipore Corporation Nanofibre contenant des structures composites
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
JP6568545B2 (ja) * 2014-06-26 2019-08-28 イー・エム・デイー・ミリポア・コーポレイシヨン 増強された汚れ保持容量を有するフィルタ構造
KR102206959B1 (ko) 2015-04-17 2021-01-25 이엠디 밀리포어 코포레이션 접선방향 유동 여과 모드에서 작동되는 나노섬유 한외여과막을 사용하여 샘플에서 목적하는 생물학적 물질을 정제하는 방법
ES2912128T3 (es) * 2016-03-30 2022-05-24 Tintometer Gmbh Dispositivo de medición de la turbidez compensatoria y procedimiento de utilización
CN109069952A (zh) 2016-07-11 2018-12-21 惠普发展公司，有限责任合伙企业 泡沫合并通气口
US11141398B2 (en) 2017-01-08 2021-10-12 The United States Government As Represented By The Department Of Veterans Affairs Methods for decreasing injuries associated with intraoperative hypotension

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617124A (en) * 1982-07-13 1986-10-14 Pall Corporation Polymeric microfibrous filter sheet, preparation and use
US4915839A (en) * 1984-03-15 1990-04-10 Cuno, Incorporated Process for surface modifying a microporous membrane
US4954256A (en) * 1989-05-15 1990-09-04 Pall Corporation Hydrophobic membranes
US5126054A (en) * 1990-05-24 1992-06-30 Pall Corporation Venting means

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL296324A (fr) * 1962-08-06
US3353682A (en) * 1966-02-28 1967-11-21 Pall Corp Fluid-permeable fibrous multilayer materials and process of making the same
US3592245A (en) * 1968-09-24 1971-07-13 American Home Prod Universal dispensing device for intravenous medications
US3803810A (en) * 1972-05-01 1974-04-16 Pall Corp Liquid-gas separator and filter
US3882026A (en) * 1972-08-14 1975-05-06 American Hospital Supply Corp Hydrophobic filter device for medical liquids
US4203848A (en) * 1977-05-25 1980-05-20 Millipore Corporation Processes of making a porous membrane material from polyvinylidene fluoride, and products
FI70421C (fi) * 1978-05-15 1986-09-19 Pall Corp Foerfarande foer framstaellning av skinnfria hydrofila i alkohol oloesliga polyamidmembraner polyamidhartsmembranhinna filterelement och gjuthartsloesning
US4702840A (en) * 1982-02-05 1987-10-27 Pall Corporation Charge modified polyamide membrane
US4707266A (en) * 1982-02-05 1987-11-17 Pall Corporation Polyamide membrane with controlled surface properties
US4568366A (en) * 1983-08-30 1986-02-04 Baxter Laboratories, Inc. In-line filter
DE3578502D1 (de) * 1984-03-15 1990-08-09 Asahi Medical Co Filtereinheit zum abtrennen von leukozyten.
US4618533A (en) * 1984-11-30 1986-10-21 Millipore Corporation Porous membrane having hydrophilic surface and process
US4774132A (en) * 1986-05-01 1988-09-27 Pall Corporation Polyvinylidene difluoride structure
US4798676A (en) * 1986-12-19 1989-01-17 Pall Corporation Low pressure drop bacterial filter and method
US5019260A (en) * 1986-12-23 1991-05-28 Pall Corporation Filtration media with low protein adsorbability
US4964989A (en) * 1986-12-23 1990-10-23 Pall Corporation Membranes with low protein adsorbability
US4906374A (en) * 1986-12-23 1990-03-06 Pall Corporation Filtration media with low protein adsorbability
US4886836A (en) * 1987-06-03 1989-12-12 Pall Corporation Activated medium with low non-specific protein adsorption
US4925572A (en) * 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US5105993A (en) * 1989-12-29 1992-04-21 La Haye Laboratories, Inc. Disposable medical dispenser with a filtering dispenser nozzle
US5252222A (en) * 1990-12-03 1993-10-12 Pall Corporation Filter for parenteral systems and method of using thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617124A (en) * 1982-07-13 1986-10-14 Pall Corporation Polymeric microfibrous filter sheet, preparation and use
US4915839A (en) * 1984-03-15 1990-04-10 Cuno, Incorporated Process for surface modifying a microporous membrane
US4954256A (en) * 1989-05-15 1990-09-04 Pall Corporation Hydrophobic membranes
US5126054A (en) * 1990-05-24 1992-06-30 Pall Corporation Venting means

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021644A1 (fr) * 1994-02-10 1995-08-17 Roland Wex Filtre a sang
US5622626A (en) * 1994-04-15 1997-04-22 Pall Corporation Multiple compartment filter and method for processing parenteral fluid
WO1997025084A1 (fr) * 1996-01-11 1997-07-17 Beth Israel Deaconess Medical Center Utilisation d'un filtre integre dans la preparation de melanges d'addition nutritifs entiers
US6074560A (en) * 1996-01-11 2000-06-13 Beth Israel Deaconess Medical Center, Inc. Use of an in-line filter in the preparation of total nutrient admixtures
EP1684716A1 (fr) * 2003-11-05 2006-08-02 The Australian National University Dispersions et leurs procedes de preparation
EP1684716A4 (fr) * 2003-11-05 2009-04-22 Univ Australian Dispersions et leurs procedes de preparation
WO2007008629A3 (fr) * 2005-07-11 2007-06-07 Hewlett Packard Development Co Separation de liquides et de gaz d'avec des mousses
WO2007008629A2 (fr) * 2005-07-11 2007-01-18 Hewlett-Packard Development Company, L.P. Separation de liquides et de gaz d'avec des mousses
DE102009045403B4 (de) 2009-10-06 2022-08-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung zum Trennen von Gas und Flüssigkeit und deren Verwendungen
EP2314332A1 (fr) * 2009-10-21 2011-04-27 Gambro Lundia AB Système de délivrance de fluide médical
WO2011048052A1 (fr) * 2009-10-21 2011-04-28 Gambro Lundia Ab Système d'administration de fluide médical
CN102711863A (zh) * 2009-10-21 2012-10-03 甘布罗伦迪亚股份公司 医用流体输送系统
EP3444000A1 (fr) * 2012-03-29 2019-02-20 Saint-Gobain Performance Plastics Corporation Appareil filtre d'aiguille
US10568810B2 (en) 2012-03-29 2020-02-25 Saint_Gobain Performance Plastics Corporation Needle filter apparatus
WO2020160014A1 (fr) * 2019-01-29 2020-08-06 Donaldson Company, Inc. Système et procédé de désaération

Also Published As

Publication number Publication date
DE69326947D1 (de) 1999-12-09
CA2132422A1 (fr) 1993-11-11
EP0637986B1 (fr) 1999-11-03
GB9420642D0 (en) 1994-11-30
JP3169612B2 (ja) 2001-05-28
GB2280860A (en) 1995-02-15
EP0637986A1 (fr) 1995-02-15
GB2280860B (en) 1996-05-08
DE69326947T2 (de) 2000-02-24
JPH07506371A (ja) 1995-07-13
CA2074692A1 (fr) 1993-10-30
CA2132422C (fr) 2002-01-29
US5536413A (en) 1996-07-16
EP0637986A4 (fr) 1996-04-24

Similar Documents

Publication Publication Date Title
CA2132422C (fr) Methode et dispositif pour traiter une solution medicamenteuse parenterale contenant une emulsion
EP0489403B1 (fr) Filtre pour système d'infusion
US5622626A (en) Multiple compartment filter and method for processing parenteral fluid
US5679264A (en) Gas plasma treated porous medium and method of separation using same
EP0479187B1 (fr) Filtre pour la filtration de fluide
US7850635B2 (en) Low hydraulic resistance cartridge
EP0419346B1 (fr) Filtre pour la purification des plaquettes
US3483867A (en) Artificial glomerulus and a method for treating blood
EP0057907B1 (fr) Dispositif de séparation des composants sanguins
US5302299A (en) Biological semi-fluid processing assembly
JPH0620499B2 (ja) 移動するガス流から粒子物質を除去するためのフイルタおよび方法
JP2002526172A (ja) 生物学的流体フィルターおよびシステム
GB2052287A (en) Medical filtering device
EP0887098A2 (fr) Milieu poreux traité au plasma gazeux et prcédé de séparation utilisant un tel milieu
WO2002011855A1 (fr) Filtre
JP3272099B2 (ja) ブラジキニン吸着体
RU2046646C1 (ru) Мембранный аппарат для разделения и очистки крови
JPH0783767B2 (ja) 血液浄化装置

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA GB JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2132422

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 9420642.2

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 1993910894

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993910894

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993910894

Country of ref document: EP